| [1] |
Aron-Wisnewsky J,Minville C,Tordjman J, et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese[J]. Hepatol, 2012, 56(1):225-233.
|
| [2] |
Nishiyama Y,Goda N,Kanai M, et al. HIF-1α induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice[J]. Hepatol, 2012, 56(2):441-447.
|
| [3] |
Loboda A,Jozkowicz A,Dulak J. HIF-1 and HIF-2 transcription factors--similar but not identical[J]. Mol Cells, 2010, 29(5):435-442.
|
| [4] |
De Minicis S,Day C,Svegliati-Baroni G. From NAFLD to NASH and HCC: pathogenetic mechanisms and therapeutic insights[J]. Curr Pharmaceut Des, 2013, 19(29):5239-5249.
|
| [5] |
Rosmorduc O,Fartoux L. HCC and NASH: how strong is the clinical demonstration[J]. Clin Res Hepatol Gastroenterol, 2012, 36(3):202-208.
|
| [6] |
Said A,Ghufran A. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma[J]. World J Clin Oncol, 2017, 8(6):429-436.
|
| [7] |
Alexander J,Torbenson M,Wu TT, et al. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-alcoholic liver: a clinical and pathological study[J]. J Gastroenterol Hepatol, 2013, 28(5):848-854.
|
| [8] |
Sanyal A,Poklepovic A,Moyneur E, et al. Population-based risk factors and resource utilization for HCC: US perspective[J]. Curr Med Res Opin, 2010, 26(9):2183-2191.
|
| [9] |
Younossi ZM,Otgonsuren M,Henry L, et al．Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology, 2015, 62(6):1723-1730．
|
| [10] |
Singal AG,El-Serag HB．Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice[J]．Clin Gastroenterol Hepatol, 2015, 13(12):2140-2151.
|
| [11] |
Younossi ZM,Koenig AB,Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84.
|
| [12] |
Estes C,Razavi H,Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology, 2018, 67(1):123-133.
|
| [13] |
Turnbull CD. Intermittent hypoxia, cardiovascular disease and obstructive sleep apnoea[J]. J Thorac Dis, 2018, 10(Suppl 1):S33-39.
|
| [14] |
Liu Y,Ma Z,Zhao C, et al. HIF-1α and HIF-2α are critically involved in hypoxia-induced lipid accumulation in hepatocytes through reducing PGC-1α-mediated fatty acid β-oxidation[J]. Toxicol Lett, 2014, 226(2):117-123.
|
| [15] |
Cao R,Zhao X,Li S, et al. Hypoxia induces dysregulation of lipid metabolism in HepG2 cells via activation of HIF-2α[J]. Cell Physiol Biochem, 2014, 34(5):1427-1441.
|
| [16] |
Baguet JP,Barone-Rochette G,Tamisier R, et al. Mechanisms of cardiac dysfunction in obstructive sleep apnea[J]. Nat Rev Cardiol, 2012, 9(12):679-688.
|
| [17] |
Yang SL,Wu C,Xiong ZF, et al. Progress on hypoxia-inducible factor-3: its structure, gene regulation and biological function (review)[J]. Mol Med Rep, 2015, 12(2):2411-2416.
|
| [18] |
Ramakrishnan SK,Shah YM. A central role for hypoxia-inducible factor (HIF)-2α in hepatic glucose homeostasis[J]. Nutr Healthy Aging, 2017, 4(3): 207-216.
|